Kyverna Therapeutics, Inc. Depreciation
Kyverna Therapeutics, Inc. (KYTX) reported Depreciation of $1.10 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-03-26
- Kyverna Therapeutics, Inc. depreciation for fiscal 2025 was $1.10M, a 450.00% increase from fiscal 2024.
- Kyverna Therapeutics, Inc. depreciation for fiscal 2024 was $200.00K, a 77.78% decline from fiscal 2023.
- Kyverna Therapeutics, Inc. depreciation for fiscal 2023 was $900.00K.
| Period end | Depreciation 12 month | Depreciation 12 month as first filed |
|---|---|---|
| 2025-12-31 | $1.10M 10-K · filed 2026-03-26 | |
| 2024-12-31 | $200.00K 10-K · filed 2026-03-26 | $1.20M 10-K · filed 2025-03-27 |
| 2023-12-31 | $900.00K 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |